|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to evaluate the potential associations of sHJV and hepcidin with inflammation, iron parameters and erythropoietin requirement in prevalent HD patients with HCV.
|
28130911 |
2018 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared to anti-EPO negative cases, anti-EPO positive patients had higher frequency of anemia (70.0% vs 34.9%, P=0.030), lower EPO concentrations (median 16.35 vs 30.65 mU/mL, P=0.005), and higher HCV RNA viral load (median 891.5X10<sup>3</sup> vs 367.5X10<sup>3</sup> IU/mL, P=0.016).
|
28603097 |
2017 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
After a 12-week course of PrOD therapy, during which ribavirin therapy was tapered and then discontinued at week 10 and subcutaneous epoetin alfa was administered for anemia control from weeks 4 to 12, the patient's HCV viral load was undetectable; a sustained virologic response at 12 weeks (SVR12) was noted.
|
28947525 |
2017 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the impact of epoetin beta (EPO) on sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with peginterferon-ribavirin (RBV).
|
26700738 |
2016 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy.
|
25227310 |
2014 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among genotype 1-infected patients, characteristics that were negatively associated with SVR independently included baseline HCV viral load >2 million IU/mL [adjusted odds ratio (AOR) 0.41, 95% CI 0.2-0.7], Black race [AOR 0.56 (0.3-0.96)], diabetes [AOR 0.42 (0.2-0.9)], baseline anaemia [AOR 0.42 (0.2-0.97)], serum aspartate aminotransferase/alanine aminotransferase ratio ≥1.2 [AOR 0.48 (0.2-0.97)] and use of zidovudine [AOR 0.41 (0.2-0.9)]; characteristics positively associated with SVR included a starting dose of ribavirin ≥1000-1200 mg/day [AOR 2.0 (1.1-3.7)] and erythropoietin use during treatment [AOR 2.9 (1.6-5.0)].
|
24127691 |
2013 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients.
|
23583759 |
2013 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Treatment of hepatitis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which has been managed by reducing ribavirin dose and/or erythropoietin therapy.
|
23924660 |
2013 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
At week 4, undetectable HCV RNA (29% vs 25%) and mean RBV trough concentration (2.48 vs 2.14 μg/mL) were comparable in both arms, whereas mean hemoglobin decay was less pronounced in the RBV induction plus erythropoietin arm than in the RBV standard dosing arm (-1.7 vs -2.3 mg/dL; P < .005).
|
22807523 |
2012 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multivariate analysis demonstrated that anti-HCV status was linked to the time on haemodialysis, previous kidney transplantation and the presence of anti-HBc antibodies, whereas erythropoietin therapy and carrying out dialysis in dedicated spaces seem to protect against HCV infection.
|
21097646 |
2011 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with HCV genotype 1 infection who develop anemia or experience a hemoglobin decline >30 g/L during weeks 5-48 of therapy achieve higher virological responses to pegylated interferon and ribavirin therapy that are unrelated to erythropoietin use.
|
21480317 |
2011 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis.
|
20652232 |
2010 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The proportional cost of treating hepatitis C when using epoetin to treat RIA is significant in genotype 2 or 3 patients.
|
17559739 |
2007 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus (HCV) infection has been identified as the major cause of chronic liver disease among patients on chronic hemodialysis (HD), despite the important reduction in risks obtained by testing candidate blood donors for anti-HCV antibodies and the use of recombinant erythropoietin to treat anemia.
|
16648896 |
2006 |